Hims & Hers HealthHIMS
About: Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
Employees: 1,046
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
226% more first-time investments, than exits
New positions opened: 124 | Existing positions closed: 38
55% more capital invested
Capital invested by funds: $2.56B [Q3] → $3.96B (+$1.4B) [Q4]
24% more funds holding
Funds holding: 304 [Q3] → 378 (+74) [Q4]
23% more repeat investments, than reductions
Existing positions increased: 128 | Existing positions reduced: 104
11.17% more ownership
Funds ownership: 66.8% [Q3] → 77.98% (+11.17%) [Q4]
0% more call options, than puts
Call options by funds: $384M | Put options by funds: $383M
25% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 6 (-2) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
B of A Securities Allen Lutz 86% 1-year accuracy 12 / 14 met price target | 57%downside $21 | Underperform Maintained | 20 Feb 2025 |
Canaccord Genuity Maria Ripps 79% 1-year accuracy 26 / 33 met price target | 38%upside $68 | Buy Maintained | 19 Feb 2025 |
Morgan Stanley Craig Hettenbach 33% 1-year accuracy 2 / 6 met price target | 22%upside $60 | Equal-Weight Downgraded | 18 Feb 2025 |
Citigroup Daniel Grosslight 41% 1-year accuracy 9 / 22 met price target | 49%downside $25 | Sell Downgraded | 10 Jan 2025 |
BTIG David Larsen 71% 1-year accuracy 12 / 17 met price target | 29%downside $35 | Buy Initiated | 7 Jan 2025 |
Financial journalist opinion
Based on 54 articles about HIMS published over the past 30 days









